Welcome To The Abbatis Bioceuticals Royal Hall

Welcome To The Abbatis Bioceuticals Royal Hall
Posted by Clay Death on 08 Apr, 2014 17:06
Welcome to the Abbatis Bioceuticals Royal Hall.

Here we will share and list information about this great Vancouver based Bioceutical firm that is at the forefront in then the cannabis space.

Please post away and fun.

#1 Reply
Posted by Clay Death on 08 Apr, 2014 17:08
here is a link to Abbatis Bioceuticals website:

http://www.abattis.com/s/home.asp

much more information and charts to follow.

#2 Reply
Posted by Clay Death on 08 Apr, 2014 17:15
I have added breaking news ticker about medical marijuana at the top of the page.

to get the full article just click on the headline. it blinks every 8 seconds.

I will add 2-3 more breaking news tickers at the top. stay tuned.

this is current and breaking news.

#3 Reply
Posted by Clay Death on 08 Apr, 2014 17:25
more news out today from Abbatis Bioceuticals Corporation:

Abattis Aims to Become Leader in Cannabis Testing with Acquisition

April 8, 2014
by admin
Filled in: CannabisFN

Abattis Bioceuticals Corp. (OTC: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing and marketing cannabis and related products and services, recently announced the acquisition of a controlling 51% stake in Washington-based Phytalytics LLC. The move could enable the company to capitalize on the growing market for cannabis compliance testing.

Under Washington State’s Initiative 502 Section 11, every licensed marijuana producer and processor must submit representative samples of marijuana, useable marijuana, or marijuana-infused products produced or processed by the licensee to an independent, third-party testing laboratory meeting the accreditation requirements established by the WSLCB for inspection and testing.

Dr. Michelle Sexton, Founder and CEO of Phytalabs, was instrumental in developing the checklist and protocols for the certification process for an analytics lab for the WSLCB that approves state licensing of adult and medicinal marijuana. Dr. Sexton was also the editor and technical advisor of American Herbal Pharmacopoeia and a board member of the Americans for Safe Access Foundation.

Other members of the Phytalabs team also have extensive industry experience that should prove invaluable. Dr. Kaleb Lund, Science Director of Phytalabs, has 10 years of analytical testing experience in the herbal supplements industry, while Ms. Lauren Hilty, CPA, Treasurer and Accountant, has been a consultant with the Federal Depository Insurance Corporation (“FDIC”) to establish marijuana banking rules.

Currently, Phytalytic is in the process of making an application to the WSLCB for an analytics laboratory testing license in order to provide government mandated testing of cannabis and all other cannabis related derivatives. While the company hasn’t provided guidance in terms of a timeline, the team’s background suggests that the approval process could happen soon rather than later.

Shares of Abattis are trading up 1.8% mid-way through Tuesday’s session and up more than 86% over the past month.

CannabisFN.com, owned by TDM Financial, is a leading provider of cannabis news and insights. CannabisFN.com may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. View Full Disclaimer

#4 Reply
Posted by Wingswomennbeer on 08 Apr, 2014 19:35
G ' afternoon ClayDeath, happy to contribute here

#5 Reply
Posted by Clay Death on 08 Apr, 2014 19:38
welcome to Camelot Wingswomennbeer. I am glad you found Camelot.

we can all stay in touch and al keep sharing with the world info about Abbatis Pharmaceutical Corporation.

thanks so much for your support.

#6 Reply
Posted by Clay Death on 08 Apr, 2014 19:39
this is an awesome site.

you start to notice Abattis Pharmaceutical the second you click on this link:

http://www.cannabisfn.com/

#7 Reply
Posted by Clay Death on 08 Apr, 2014 19:50
ATT:CNX; ATTBF:OTC

Shares Outstanding… 47.6M

Abattis remains a top pick out on the West Coast in the Medical Marijuana scene. I have ATT/ATTBF firmly entrenched in the MMJ sector and expect Abattis to follow a track similar to PLPL. Yes I have said PLPL is a top recreation pick, but PLPL is one of the few companies that I think will transcend both recreation and medical cannabis. Abattis has methodically developed a plan of attack and is now executing on that plan.

•Received their controlled substances licence which allows them to develop extracts, concentrates and oils from the cannabis they grow.
•Expanded into the US markets developing strategic alliances with companies like Transbyte ERBB
•Owns arguably the top one of the top vegetable concentration technologies which can be readily applied to cannabis.
•Own Vertical Designs, a patented vertical growing technology they plan on licencing to other growers. Vertical Designs growing technology maximizes space and light efficiencies allowing for the greatest yields of indoor hydroponics systems.
Abattis has emerged as the market leader out west and is entrenching themselves as one of the top medical cannabis companies in North America, let alone Canada.

#8 Reply
Posted by Clay Death on 08 Apr, 2014 20:54
breaking news on Abbatis for those who may have missed it:

http://marijuanaindex.org/industry-news-item/

Abattis Completes Acquisiton Of Controlling Interest In Phytalytics LLC

(via Thenewswire.ca)

VANCOUVER, BC / TNW-ACCESSWIRE / April 7 , 2014 / Abattis Bioceuticals Corp. ("Abattis" or the "Company") (CSE: ATT) (OTC: ATTBF), a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, today announced that further to its previous press release dated March 6, 2014 disclosing it had entered into consulting agreements with the principals of Phytalytics LLC of Kirkland, Washington, USA, the Company has acquired a 51% membership interest in Phytalytics LLC (doing business as Phytalab.com ).

Phytalytics and its principals, Dr. Michelle Sexton, Dr. Kaleb Lund and Lauren Hilty, Sr. Accountant, will be making an application to the Washington State Liquor Control Board ("WSLCB") for an analytics laboratory testing license in order to provide government mandated testing of cannabis and all other cannabis related derivatives under State Initiative 502. Under State Initiative 502 Section 11, every licensed marijuana producer and processor must submit representative samples of marijuana, useable marijuana, or marijuana-infused products produced or processed by the licensee to an independent, third-party testing laboratory meeting the accreditation requirements established by the WSLCB, for inspection and testing to certify compliance with standards adopted by the WSLCB.

Dr. Sexton has long advocated for improved quality assurance for herbal products and was a technical advisor for American Herbal Pharmacopoeia on the "Cannabis Monograph: Standards on Identity, Analysis and Quality Control." http://www.herbal-ahp.org/

Dr. Sexton recently consulted to the Washington State Liquor Control Board for development of the certification process for laboratories that provide analysis of Cannabis and related products distributed under SI502. Phytalytics was developed on the platform of Good Laboratory Practice (GLP) guidelines, which Dr. Sexton introduced to the Cannabis industry. The combined botanical and scientific backgrounds of Drs Sexton and Lund, along with the partnership and expertise of Abattis, leverage PhytaLab to continue to be pace setters in this burgeoning industry.

Drs. Lund and Sexton, of Phytalytics, stated, "We are very pleased to leverage our combined botanical and scientific backgrounds with the expertise of Abattis so that PhytaLab will continue to be a pacesetter in this burgeoning industry."

Mike Withrow, CEO of Abattis Bioceuticals Corp., stated, "We are delighted to be able to consolidate and align the membership interests in Phytalytics and looking forward to a mutually beneficial relationship. Moving forward, our new analytics lab testing team in Washington will have the support of the Company's resources to secure a WSLCB license in addition to sourcing the requisite equipment to scale its operations as demand for its services escalate."

About Phytalytics LLC..

Phytalytics was founded in 2011 and pioneered the movement to help define quality control of Cannabis and related products in Washington State. PhytaLab is an industry leader with regard to experience and validation know-how of in State mandated testing of Flowers, Extracts, Edibles, Liquids, Topicals of Cannabis and Cannabinoids. PhytaLab has taken great care to maximize HPLC resolution so there is no overlap of compounds guaranteeing accurate potency measurements, foreign material inspection, moisture content, Microbiological Screening and Residual Solvents Testing.

PhytaLab utilizes high-performance liquid chromatography (HPLC) to separate and quantify the relevant cannabinoids in samples. It is the most accurate, optimal and straightforward method for analysis of the authentic plant compounds, including acidic and neutral forms. This platform is the standard for testing of compounds that can change upon heating, and therefore does not heat the sample before analysis. For more information, visit the Company's website at www.phytalab.com

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at www.abattis.com.

For further information, contact the Company's CEO, Michael Withrow at (778) 896-6536 or at mike.withrow@abattis.com.

ON BEHALF OF THE BOARD

"Mike Withrow"_____________

Mike Withrow

President & CEO

For information please contact:

Mike Withrow

P: 778.896.6536
www.abattis.com

#9 Reply
Posted by Clay Death on 10 Apr, 2014 18:47
this news today from Abbatis is simply massive. it got lost in all that blood bath today.

well it wont be lost much longer. tomorrow the world will find out about it.

http://marijuanaindex.org/industry-news-item/

April 10, 2014 - 9:15 AM EDT

Abattis Announces Completes Agreement With Experion

(via Thenewswire.ca)

Vancouver, BC - April 10th, 2014 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CSE: ATT), through its wholly owned subsidiary, Northern Vine Canada Inc. ("Northern Vine"), announces that it has entered into a share exchange agreement with Experion Biotechnologies Inc. ("Experion"). Pursuant to the terms of the agreement, Experion and Northern Vine have exchanged 25% of each parties' issued and outstanding common shares. Abattis maintains a 75% ownership in Northern Vine.

Experion is located in Greater Vancouver and is nearing the completion of its Marijuana for Medical Purposes Regulations "MMPR" licence application with Health Canada. Together, Northern Vine and Experion are well positioned to capitalize on the growing trend towards marijuana legalization in the U.S., and medical use in Canada as licensed producers.

Northern Vine, a lab and compounding pharmacy with patented compositions, owns various Natural Health Product licenses for use in the nutraceutical markets. Northern Vine has one remaining outstanding item to complete as required by Health Canada in respect of its controlled substance licence application.

It is anticipated that Experion will provide cannabis for Northern Vine's research and development activities upon receiving its MMPR licence. Experion will also allocate a portion of its 10 acre site for the expansion of Northern Vine's future processing facility and any expansion requirements needed to satisfy cultivation demand in the foreseeable future.

Mike Withrow, President and CEO of Abattis stated: "This is a strategic partnership that links our pending Controlled Substance Licence to another MMPR Application in order to further expand our business potential. This agreement provides the Company with more control of a broader variety of raw materials, for products derived from marijuana, to be processed at our planned botanical drug facility in Quebec. This partnership also creates synergy by joining cultivation with formulation sciences."

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

About Experion Biotechnologies Inc.

Experion Biotechnologies Inc. is a team of innovators dedicated to producing, procuring, and providing medical products derived from Cannabis of superior quality in a consistent and timely manner to patients across Canada in accordance with Health Canada regulations. Its current facilities in the Greater Vancouver Area are ready to operate under strict guidelines with standardized operating protocols as a commitment to the quality patients require.

For further information, contact the Company's CEO, Michael Withrow at (604) 538-6650

or at mike.withrow@abattis.com.

#10 Reply
Posted by Clay Death on 11 Apr, 2014 08:55
another rough day in the markets and in the cannabis space but there seems to be some recovery in the process now.

ATTBF is trying to hold its ground now and stage a recovery.

#11 Reply
Posted by Clay Death on 11 Apr, 2014 22:20
well no recovery possible on a day when the markets went to hell in a hand basket again.

biotechs and cannabis sector stocks got hit pretty hard.

this creates a lot of opportunities for next week.

#12 Reply
Posted by Clay Death on 11 Apr, 2014 23:27
top story on cannabis financial news:

http://www.cannabisfn.com/abattis-gains-potential-exposure-to-mmpr-via-subsidiary-share-exchange/#.U0jAL2dOWpo

#13 Reply
Posted by Clay Death on 12 Apr, 2014 09:09
Abattis Gains Potential Exposure to MMPR via Subsidiary Share Exchange

 Ryan Allway

📅 April 11th, 2014

 Feature Stories

7

Abattis Bioceuticals Corp. (OTC: ATTBF), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, patented equipment, and consulting services to medicinal marijuana markets in North America, recently announced a share exchange agreement between its Northern Vine subsidiary and Experion Biotechnologies Inc.

Under the fair and equal value exchange agreement, Abattis Bioceuticals gained a 25% stake in Experion – who is in the late stages of an MMPR application to become a Licensed Producer in Canada – by trading a 25% stake in its privately-held subsidiary Northern Vine. The move adds to the “Grow” component of Abattis Bioceuticals GDERS (“Grow, Dry, Extract, Refine, Science/Sell”) business model.

Canada transitioned from its old Marihuana Medical Access Regulations (“MMAR”) to Marihuana for Medical Purposes Regulations (“MMPR”) on April 1, 2014. The move will force 40,000 Canadian medical marijuana users to begin purchasing product from Licensed Producers rather than from the government or growing it on their own in their homes in order to tighten the market’s regulation.

The MMPR will also greatly expand access to the drug for medical purposes. In fact, Health Canada expects the number of medical marijuana users to grow to 450,000 with the market reaching $1.3 billion in size by 2024. There are only 12 approved Licensed Producers right now with approximately 450 outstanding applications, although the barriers to entry are very high leading to many denials.

“This is a strategic partnership that links our pending Controlled Substance License to another MMPR Application in order to further expand our business potential,” said Abattis Bioceuticals President and CEO Mike Withrow. “This agreement provides the company with more control of a broader variety of raw materials, for products derived from marijuana, to be processed at our planned botanical facility in Quebec. This partnership also creates synergy by joining cultivation with formulation sciences.”

#14 Reply
Posted by Clay Death on 12 Apr, 2014 18:38
http://finance.yahoo.com/news/tranzbyte-attbf-sign-letters-intent-140000955.html

Tranzbyte and ATTBF Sign Letters of Intent Creating Strategic Production, Sales, and Distribution Partnership

.

Marketwired
Tranzbyte Corporation
March 21, 2014 10:00 AM

TEMPE, AZ--(Marketwired - Mar 21, 2014) - Tranzbyte Corporation (OTC Pink: ERBB)(PINKSHEETS: ERBB) (http://www.bloomberg.com/quote/ERBB:US) announced today that it has signed a Letter of Intent to form a strategic partnership with Abattis (OTC Pink: ATTBF)(PINKSHEETS: ATTBF) (CSE: ATT) (http://www.bloomberg.com/quote/ATTBF:US) to sell, market or otherwise license one another's products in their respective regions. Once the arrangement is completed, Tranzbyte will have access to Abattis's expanding suite of bio-ceutical grow products found in the Biocube Green Grow Systems for cultivation (LED's, Nutrients - Natures Juice). In addition Abattis owns proprietary flash freeze extraction technology, which produces high-grade cannabis and other botanical extracts. Conversely, Abattis will have the Canadian rights to distribute ZaZZZ™ and will pair Tranzbyte's Jurassic O2 water systems with its Biocube Green Grow Systems sales efforts in the US.

"When one looks at the obvious NAFTA synergy, this relationship makes all the sense in the world. Abattis is a powerhouse in Canada; we are stronger in the US. From cross-promotion to extended sales and marketing, the opportunities that will be created with the two companies working together will be nothing short of phenomenal," says Stephen Shearin, Tranzbyte COO.

According to David Gwyther, Tranzbyte's president, "I am very impressed with Abattis's commitment to the research, development, and marketing capability they've shown involving their proprietary, natural health and wellness solutions which address chronic illnesses through targeted nutritional support and, thus, fit perfectly into Tranzbyte's future plans. Working together leverages our collective visions for this vast and expanding marketplace."

In addition, Abattis owns flash-freeze extraction technology that produces the highest grade flower extract which is in high demand today. Conventional extraction methods require heat and solvents which can increase liabilities for dispensaries who extract on-site. The Northern Vine cold press extraction owned by Abattis is exactly what the industry needs to fulfill patient orders in a clean safe manner. "This offers dispensaries and growers a complete end-to-end solution of cutting-edge grow technologies and plant analysis," comments Mike Withrow, CEO of Abattis. "In addition, with the rights to the ZaZZZ™ automated vending opportunity as the regulatory climate evolves in Canada, we open up a lot of growth potential. Merging the efforts of the leading companies in each country should build real shareholder value for each company."

In other news, the medical and social marijuana division, formally, Altitude Organix, is changing to American Green™. The company has purchased both domain and trademark rights to the name. Its new logo (below) has been designed to evoke a time before prohibition, when hard working people had more leeway in their choice of medicine and their pursuit of happiness. American Green™ is carrying on the American Dream.

Tranzbyte encourages all folks wishing to follow the progress of Tranzbyte, Altitude Organix, and its other subsidiaries and divisions to visit the Tranzbyte website at www.tranzbyte.com and sign up to receive our 'Email Alerts' which are sparingly sent to interest-holders periodically. Just click on the orange 'contact' button after arriving at the company's website. Mobile users can also sign up by navigating to the company's website on their android smart phone or iPhone."

Also, shareholder and other interest-holders may track the progress of the pending delivery of our fully automated ZaZZZ™ Machine by following us on Twitter @Tranzbyte or @American__Green (two underscores.)

ABOUT TRANZBYTE

The Tranzbyte Corporation (www.tranzbyte.com) is a driving force behind Altitude Organix, American Green, OneBode, The YO! Debit Card, and BancoLibre. The company expects to continue its plan to acquire, hold, or spin out successful divisions in what has been described in previous news releases as "dividend farming," Companies that qualify and decide to become public on their own will agree to carve out shares for Tranzbyte and dividends for their ERBB shareholders.

Tranzbyte also houses the company's 10-year-old technology division which is actively engaged in the sale of its optical media enhancement products to potential customers in the US and Asia. Products in the Tranzbyte division include FLASHAlbum™ and FlixStix -- technologies that the company plans to be incorporated into the Company's ZaZZZ Machine while enabling distributors of optical media (CDs, DVDs, etc.) to consolidate the best features of each medium onto a single content-protected USB flash drive.

ABOUT ABATTIS BIOCEUTICALS CORP.

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. We follow strict Standard Operating Protocols and adhere to the Law's of Canada and Foreign Jurisdictions. For more information, visit the Company's website at www.abattis.com.